These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26254144)

  • 21. Schizophrenia drug gets negative results for negative symptoms.
    Kingwell K
    Nat Rev Drug Discov; 2014 Apr; 13(4):244-5. PubMed ID: 24687052
    [No Abstract]   [Full Text] [Related]  

  • 22. [Possible relevance of alterations at the cellular, neuronal connectivity and brain structure levels to the pathophysiology of schizophrenia].
    Berger E; Shiloh R; Weizman A; Munitz H
    Harefuah; 2001 Jul; 140(7):648-52. PubMed ID: 11481973
    [No Abstract]   [Full Text] [Related]  

  • 23. Dopamine receptors and schizophrenia.
    Reynolds GP
    Biochem Soc Trans; 1996 Feb; 24(1):202-5. PubMed ID: 8674664
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effects of neuroleptics on the frontal functions of schizophrenics].
    Verdoux H; Magnin E; Bourgeois M
    Ann Med Psychol (Paris); 1994 Oct; 152(8):530-4. PubMed ID: 7818228
    [No Abstract]   [Full Text] [Related]  

  • 25. Clozapine, GABA(B), and the treatment of resistant schizophrenia.
    Daskalakis ZJ; George TP
    Clin Pharmacol Ther; 2009 Oct; 86(4):442-6. PubMed ID: 19626000
    [No Abstract]   [Full Text] [Related]  

  • 26. Visual evoked potentials during the treatment with isofloxythepine.
    Libiger J; Kuba M; Zapletálek M; Dostál J
    Act Nerv Super (Praha); 1989 Apr; 31(1):34-5. PubMed ID: 2571219
    [No Abstract]   [Full Text] [Related]  

  • 27. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.
    Sharma RP; Janicak PG; Bissette G; Nemeroff CB
    Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycine reuptake inhibition: a promising therapeutic strategy in the treatment of schizophrenia?
    Chue PS; Baker GB
    Future Med Chem; 2013 Sep; 5(13):1475-7. PubMed ID: 24024940
    [No Abstract]   [Full Text] [Related]  

  • 29. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.
    Citrome L
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1551-64. PubMed ID: 21034370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine and schizophrenia.
    Crow TJ; Johnstone EC; Longden A; Owen F
    Adv Biochem Psychopharmacol; 1978; 19():301-9. PubMed ID: 29450
    [No Abstract]   [Full Text] [Related]  

  • 31. Unchanging mirror neuron activity in schizophrenia patients over 4 weeks of treatment: evidence from a 192 channel quantitative electroencephalography study.
    Mitra S; Nizamie SH; Goyal N; Tikka SK
    Biol Psychiatry; 2014 Sep; 76(6):e13-4. PubMed ID: 24503469
    [No Abstract]   [Full Text] [Related]  

  • 32. Alterations of thalamic activity in schizophrenia and in response to antipsychotic drugs: studies in the legacy of Seymour S. Kety.
    Cohen BM; Yurgelun-Todd D
    Neuropsychopharmacology; 2001 Sep; 25(3):305-12. PubMed ID: 11522459
    [No Abstract]   [Full Text] [Related]  

  • 33. Late potentials in the signal-averaged electrocardiogram in schizophrenia patients maintained on antipsychotic agents: a preliminary naturalistic study.
    Nahshoni E; Strasberg B; Imbar S; Rotem O; Gur S; Hermesh H; Weizman A
    Eur Neuropsychopharmacol; 2010 Mar; 20(3):146-52. PubMed ID: 20053540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atypical antipsychotic drugs for schizophrenia.
    Luh JY
    Mayo Clin Proc; 2003 Mar; 78(3):381-2. PubMed ID: 12630594
    [No Abstract]   [Full Text] [Related]  

  • 35. Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia.
    Mattei D; Djodari-Irani A; Hadar R; Pelz A; de Cossío LF; Goetz T; Matyash M; Kettenmann H; Winter C; Wolf SA
    Brain Behav Immun; 2014 May; 38():175-84. PubMed ID: 24509090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology and mechanism of action of existing and new neuroleptics.
    Niemegeers CJ
    Acta Psiquiatr Psicol Am Lat; 1990; 36(1-2):26-36. PubMed ID: 1981439
    [No Abstract]   [Full Text] [Related]  

  • 37. Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: reversal by clozapine.
    Ribeiro BM; do Carmo MR; Freire RS; Rocha NF; Borella VC; de Menezes AT; Monte AS; Gomes PX; de Sousa FC; Vale ML; de Lucena DF; Gama CS; Macêdo D
    Schizophr Res; 2013 Dec; 151(1-3):12-9. PubMed ID: 24257517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of schizophrenia negative symptoms: future prospects.
    Erhart SM; Marder SR; Carpenter WT
    Schizophr Bull; 2006 Apr; 32(2):234-7. PubMed ID: 16492797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microglia dysfunction in schizophrenia: an integrative theory.
    Munn NA
    Med Hypotheses; 2000 Feb; 54(2):198-202. PubMed ID: 10790752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The involvement of D-1 and D-2 dopamine receptors in the effects of neuroleptics and the pathogenesis of schizophrenia].
    Wielgosz M
    Psychiatr Pol; 1992; 26(5):357-64. PubMed ID: 1363827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.